Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test

Gut

Volumn 56, Issue 11, 2007, Pages 1579-1584

  Denis, Bernard ^a   Ruetsch, Marcel ^b   Strentz, Patrick ^b   Vogel, Jean Yves ^b   Guth, Francis ^b   Boyaval, Jean Marc ^b   Pagnon, Xavier ^b   Ebelin, Jean François ^b   Gendre, Isabelle ^b   Perrin, Philippe ^b  

^a Pasteur Hospital   (France)

^b ADECA68 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC;

ADENOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OCCULT BLOOD TEST; POPULATION RESEARCH; PRIORITY JOURNAL;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GUAIAC; HUMANS; IMMUNOCHEMISTRY; INDICATORS AND REAGENTS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 35648995357     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.126037     Document Type: Article

References (32)

1. Remontet L, Estève J, Bouvier AM, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003;51:3-30.
2. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71.
3. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
4. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood. Lancet 1996;348:1467-71.
5. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
6. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004;126:1674-80.
7. Tazi MA, Faivre J, Dassonville F, et al. Participation in faecal occult blood screening for colorectal cancer in a well defined French population: results of five screening rounds from 1988 to 1996. J Med Screen 1997;4:147-51.
8. Schlemper RJ, Kato Y, Stolte M. Diagnostic criteria for gastrointestinal carcinomas in Japan and Western countries: proposal for a new classification system of gastrointestinal epithelial neoplasia. J Gastroenterol Hepatol 2000;15:G49-57.
9. Sobin LH, Wittekind C, eds. TNM classification of malignant tumours. UICC. 6th ed. New York: Wiley-Liss, 2002.
10. AJCC cancer staging manual, 5th ed. New York: Springer, 1997.
11. AJCC cancer staging manual, 6th ed. New York: Springer, 2002.
12. UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 2004;329:133-7.
13. Launoy G, Herbert C, Vallée JP, et al. Le dépistage de masse du cancer colorectal en France. Expérience auprès de 165000 personnes dans le Calvados. Gastroenterol Clin Biol 1996;20:228-36.
14. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5.
15. Lieberman DA, de Garmo PL, Fleischer DE, et al. Colonic neoplasia in patients with nonspecific GI symptoms. Gastrointest Endosc 2000;51:647-51.
16. Denis B, Weiss AM, Peter A, et al. Quality assurance and gastrointestinal endoscopy: an audit of 500 colonoscopic procedures. Gastroenterol Clin Biol 2004;28:1245-55.
17. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006;355:1863-72.
18. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005;97:989-97.
19. Lieberman D. Race, gender, and colorectal cancer screening. Am J Gastroenterol 2005;100:2756-8.
20. Waye JD, Kahn O, Auerbach ME. Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996;6:343-77.
21. Feig SA. Adverse effects of screening mammography. Radiol Clin N Am 2004;42:807-19.
22. Robinson MHE, Hardcastle JD, Moss SM, et al. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999;45:588-92.
23. Zubarik R, Fleischer DE, Mastropietro C, et al. Prospective analysis of complications 30 days after outpatient colonoscopy. Gastrointest Endosc 1999;50:322-8.
24. Gow J. Costs of screening for colorectal cancer: an Australian programme. Health Econ 1999;8:531-40.
25. Whynes DK, Nottingham FOB screening trial. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial. J Med Screen 2004;11:11-5.
26. Wait S, Schaffer P, Seradour B, et al. The cost of breast cancer screening in France. J Radiol 2000;81:799-806.
27. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002;359:1291-300.
28. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of "Once-Only Sigmoidoscopy"-Score. J Natl Cancer Inst 2002;94:1763-72.
29. Gondal G, Grotmol T, Hofstad B, et al. The Norwegian colorectal cancer prevention (NORCCAP) screening study. Baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-42.
30. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac-based and an immunochemical fecal occult blood test in screening for colorectal cancer in a general average-risk population. Gut 2007;56:210-4.
31. Rasmussen M, Kronborg O, Fenger C, et al. Possible advantages and drawbacks of adding flexible sigmoidoscopy to Hemoccult-II in screening for colorectal cancer. Scand J Gastroenterol 1999;1:73-8.
32. Berry DP, Clarke P, Hardcastle JD, et al. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg 1997;84:1274- 6.